Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ELEV Elevation Oncology	$0.36 -5.9%	$0.35	$0.22 ▼ $3.28	$21.46M	1.43	1.50 million shs	7.89 million shs
OCX OncoCyte	$3.18 +16.3%	$3.03	$1.92 ▼ $4.75	$90.80M	0.97	59,187 shs	100,514 shs
TNYA Tenaya Therapeutics	$0.61 -11.8%	$0.51	$0.36 ▼ $4.06	$99.16M	2.91	2.70 million shs	8.88 million shs
UNCY Unicycive Therapeutics	$6.80 +14.5%	$6.39	$2.02 ▼ $11.00	$85.96M	2.01	236,272 shs	1.80 million shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ELEV Elevation Oncology	0.00%	-4.91%	+18.36%	+39.35%	-84.58%
OCX OncoCyte	0.00%	0.00%	-2.61%	-1.09%	+20.27%
TNYA Tenaya Therapeutics	0.00%	+3.83%	+37.17%	-5.11%	-77.59%
UNCY Unicycive Therapeutics	0.00%	+7.26%	+15.86%	+10.75%	+41.67%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ELEV Elevation Oncology	2.2053 of 5 stars	3.0	2.0	3.3	1.7	0.6
OCX OncoCyte	2.7412 of 5 stars	3.4	4.0	2.7	0.8	0.6
TNYA Tenaya Therapeutics	3.3661 of 5 stars	3.5	2.0	2.0	4.2	1.3
UNCY Unicycive Therapeutics	3.0323 of 5 stars	3.8	3.0	2.7	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ELEV Elevation Oncology	2.00	Hold	$3.39	834.51% Upside
OCX OncoCyte	2.75	Moderate Buy	$6.06	90.94% Upside
TNYA Tenaya Therapeutics	3.00	Buy	$6.25	925.26% Upside
UNCY Unicycive Therapeutics	3.50	Strong Buy	$60.00	782.35% Upside

Current Analyst Ratings Breakdown

Latest ELEV, TNYA, OCX, and UNCY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/10/2025	ELEV Elevation Oncology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
6/10/2025	ELEV Elevation Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Neutral
6/9/2025	ELEV Elevation Oncology	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/9/2025	ELEV Elevation Oncology	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/27/2025	UNCY Unicycive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$90.00
5/21/2025	OCX OncoCyte	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
5/21/2025	OCX OncoCyte	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$5.00 ➝ $8.00
5/13/2025	OCX OncoCyte	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.25 ➝ $4.25
5/9/2025	TNYA Tenaya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
4/25/2025	TNYA Tenaya Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/21/2025	UNCY Unicycive Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00

(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ELEV Elevation Oncology	N/A	N/A	N/A	N/A	$1.02 per share	N/A
OCX OncoCyte	$3.84M	23.63	N/A	N/A	($0.70) per share	-4.54
TNYA Tenaya Therapeutics	N/A	N/A	N/A	N/A	$1.07 per share	N/A
UNCY Unicycive Therapeutics	$680K	126.40	N/A	N/A	$0.72 per share	9.44

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ELEV Elevation Oncology	-$44.49M	-$0.82	N/A	N/A	N/A	N/A	-74.68%	-48.14%	8/5/2025 (Estimated)
OCX OncoCyte	-$60.66M	-$3.53	N/A	N/A	N/A	-1,516.06%	-215.59%	-27.23%	8/6/2025 (Estimated)
TNYA Tenaya Therapeutics	-$111.13M	-$1.16	N/A	N/A	N/A	N/A	-92.20%	-74.53%	8/14/2025 (Estimated)
UNCY Unicycive Therapeutics	-$36.73M	-$5.10	N/A	N/A	N/A	N/A	-277.30%	-61.53%	N/A

Latest ELEV, TNYA, OCX, and UNCY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	ELEV Elevation Oncology	-$0.20	-$0.24	-$0.04	-$0.24	N/A	N/A
5/14/2025	Q1 2025	UNCY Unicycive Therapeutics	-$1.40	-$0.50	+$0.90	-$0.05	N/A	N/A
5/12/2025	Q1 2025	OCX OncoCyte	-$0.24	-$0.26	-$0.02	-$0.26	$0.13 million	$2.14 million
5/7/2025	Q1 2025	TNYA Tenaya Therapeutics	-$0.18	-$0.24	-$0.06	-$0.24	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ELEV Elevation Oncology	N/A	N/A	N/A	N/A	N/A
OCX OncoCyte	N/A	N/A	N/A	N/A	N/A
TNYA Tenaya Therapeutics	N/A	N/A	N/A	N/A	N/A
UNCY Unicycive Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ELEV Elevation Oncology	0.67	19.40	19.40
OCX OncoCyte	0.20	3.74	3.70
TNYA Tenaya Therapeutics	N/A	6.68	6.68
UNCY Unicycive Therapeutics	N/A	1.64	1.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ELEV Elevation Oncology	83.70%
OCX OncoCyte	55.35%
TNYA Tenaya Therapeutics	90.54%
UNCY Unicycive Therapeutics	40.42%

Insider Ownership

Company	Insider Ownership
ELEV Elevation Oncology	8.10%
OCX OncoCyte	2.05%
TNYA Tenaya Therapeutics	48.65%
UNCY Unicycive Therapeutics	10.71%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ELEV Elevation Oncology	40	59.22 million	54.43 million	Optionable
OCX OncoCyte	120	28.60 million	28.01 million	No Data
TNYA Tenaya Therapeutics	110	162.67 million	83.53 million	Optionable
UNCY Unicycive Therapeutics	9	12.64 million	11.29 million	Not Optionable

ELEV, TNYA, OCX, and UNCY Headlines

Recent News About These Companies

Unicycive Therapeutics Inc News (UNCY) - Investing.com

June 24, 2025 | investing.com

Unicycive Therapeutics (NASDAQ:UNCY) Shares Gap Down - Time to Sell?

June 20, 2025 | marketbeat.com

Unicycive Therapeutics Inc trading halted, news pending

June 18, 2025 | msn.com

Unicycive to implement 1-for-10 reverse stock split to regain Nasdaq listing

June 18, 2025 | investing.com

Unicycive Therapeutics, Inc. Announces Reverse Stock Split

June 17, 2025 | globenewswire.com

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Short Interest Down 46.4% in May

June 15, 2025 | marketbeat.com

UNCY Q3 EPS Forecast Raised by Brookline Capital Management

June 12, 2025 | marketbeat.com

Kaplan Fox Announces an Investigation Into Unicycive Therapeutics, Inc. (UNCY) for Potential Securities Law Violations

June 11, 2025 | theglobeandmail.com

Retail investors are Unicycive Therapeutics, Inc.'s (NASDAQ:UNCY) biggest owners and were hit after market cap dropped US$28m

June 11, 2025 | finance.yahoo.com

Unicycive Shares Slide as FDA Flags Issues Related to Kidney Drug Application

June 10, 2025 | marketwatch.com

Unicycive Therapeutics stock tumbles after FDA flags manufacturing issues

June 10, 2025 | investing.com

Unicycive Therapeutics Addresses FDA Deficiencies in OLC NDA Process, Awaiting Final Decision by June 2025

June 10, 2025 | quiverquant.comQ

Unicycive Provides Update on New Drug Application for Oxylanthanum Carbonate to Treat Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

June 10, 2025 | globenewswire.com

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Sees Significant Drop in Short Interest

June 3, 2025 | marketbeat.com

What is HC Wainwright's Estimate for UNCY Q2 Earnings?

May 30, 2025 | marketbeat.com

Q4 Earnings Estimate for UNCY Issued By HC Wainwright

May 29, 2025 | marketbeat.com

Unicycive Therapeutics CEO Shalabh Gupta to Present at Upcoming Investor Conferences

May 22, 2025 | quiverquant.comQ

Unicycive Therapeutics to Present at Upcoming Investor Conferences

May 22, 2025 | globenewswire.com

Unicycive Therapeutics Announces Time Change for 2025 Annual Meeting of Stockholders

May 21, 2025 | globenewswire.com

Unicycive Therapeutics, Inc.: Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

May 14, 2025 | finanznachrichten.de

Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

May 14, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELEV, TNYA, OCX, and UNCY Company Descriptions

Elevation Oncology NASDAQ:ELEV

$0.36 -0.02 (-5.90%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$0.38 +0.01 (+3.78%)

As of 06/27/2025 07:56 PM Eastern

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.

OncoCyte NASDAQ:OCX

$3.18 +0.45 (+16.30%)

Closing price 06/17/2025

Extended Trading

$3.18 0.00 (0.00%)

As of 06/17/2025 07:21 PM Eastern

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

Tenaya Therapeutics NASDAQ:TNYA

$0.61 -0.08 (-11.84%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$0.63 +0.02 (+4.00%)

As of 06/27/2025 07:58 PM Eastern

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Unicycive Therapeutics NASDAQ:UNCY

$6.80 +0.86 (+14.48%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$6.77 -0.03 (-0.44%)

As of 06/27/2025 07:59 PM Eastern

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time